The company is heading toward earnings with one growth engine still running hot, while Bank of America sees another potential catalyst building.

The stock has stood out while the index has barely moved, but the number that matters for a portfolio is how little of its return comes from the market.

Integra's steep valuation discount meets margin gains and cost savings, but modest growth, leverage and unresolved FDA risks keep execution in focus.

Medtronic plc (NYSE:MDT) is now just one dividend increase away from becoming a Dividend King. It has raised its payout for 49 straight years, putting the company right at the doorstep of the 50-year milestone. Medtronic raised its quarterly dividend to $0.72 per share in June 2026, bringing the annual payout to $2.88. At a […]

In the most recent trading session, Medtronic (MDT) closed at $92.09, indicating a +1.64% shift from the previous trading day.

MDT vs. A: Which Stock Is the Better Value Option?

CNMD's 16% monthly rally is backed by stronger growth, margin gains and raised earnings guidance, but cash-flow and execution risks remain.

CNMD's low valuation and improved earnings outlook strengthen its appeal, but cash-flow pressure and execution risks keep the buy case measured.

CONMED raised its 2026 adjusted EPS outlook after a strong second quarter, but slower organic growth and higher financing costs keep the setup mixed.

NPCE's IGE expansion faces a regulatory delay, shifting focus to rising RNS adoption as the company works through the FDA review process.

NPCE's stronger RNS adoption, narrowing losses and AI expansion support growth, but premium valuation, liquidity and regulatory risks warrant patience.

NeuroPace's stronger RNS growth, raised 2026 guidance and AI expansion face a less certain IGE regulatory path after the FDA setback.

The biosimilar drag on Johnson & Johnson stock is shrinking, and the business underneath it is already growing at a double-digit pace.

In August 2026, a federal jury ordered Medtronic to pay US$88,000,000 in compensatory damages over injuries linked to Covidien hernia mesh, while Medtronic Canada received Health Canada approval for its Affera Integrated Mapping and Ablation System for treating atrial fibrillation and atrial flutter. The combination of a record-setting mesh verdict and the addition of a second pulsed field ablation platform highlights how Medtronic’s legal exposure contrasts with its continued product...

Medtronic (NYSE:MDT) has received Health Canada approval for its Affera Integrated Mapping System and Sphere-9 Catheter for the treatment of atrial fibrillation and atrial flutter. The licence allows commercial use of Medtronic's combined pulse field and radiofrequency ablation technologies across Canada. The Affera system provides physicians with an all-in-one mapping and ablation platform aimed at supporting procedural efficiency and patient care. The approval marks a milestone for...